David Schnell is a co-founder and Managing Director of Prospect Venture Partners, a venture capital firm dedicated to investing in and supporting emerging biomedical companies. Since 1997, Prospect has raised and managed more than a $1B of committed capital from foundations, endowments, pension funds and others to support innovative biomedical companies develop and commercialize novel products and technologies to address important unmet medical needs.

David serves or has served on the Board of Directors of Gloucester Pharmaceuticals ( NASDAQ:CELG acquired), Healtheon (NASDAQ: WBMD), Kythera Biopharmaceuticals (NASDAQ: KYTH), Microcide (NASDAQ:MCDE), Neurocrine (NASDAQ:NBIX), NGM Biopharmaceuticals, Rinat Neuroscience (NYSE:PFE acquired), Senomyx (NASDAQ:SNMX), Trubion (NYSE: EBS acquired), Amira Pharmaceuticals (NYSE: BMS acquired) and several other privately-held companies.

Previously, David served as a Partner at venture capital firm Kleiner Perkins Caufield & Byers (KPCB), focusing on biotechnology and health care information technology investing from 1993-1997. Prior to KPCB, David spent seven years at Sandoz Pharmaceuticals (presently Novartis) in executive management positions in product marketing, strategic operations and business development in the US and Switzerland. In addition to his operating roles at Sandoz, David managed the company's global venture capital investing activities in affiliation with Avalon Medical Partners from 1992-1993. While at KPCB, David co-founded and served as the CEO of Healtheon Corporation, a pioneering health care transaction company that subsequently went public, and later merged with WebMD in a $6 billion transaction.

David is a Principal Partner in the San Francisco Giants, and Manager of Schnell Baseball LLC, a limited partner in SFBA, LP. David is also the author of the award-winning children’s book, "The Night Before Baseball at the Park by the Bay”. David serves on the Advisory Council for Make-A-Wish Foundation (Greater SF Bay Area), a non-profit organization dedicated to fulfilling wishes of children with life-threatening medical conditions, and previously served on the Dean of Harvard Medical School’s Therapeutics Advisory Council.

David received an M.D. from Harvard Medical School in 1987, an M.A. in Health Services Research from Stanford University School of Medicine, and a B.S. in Biological Sciences from Stanford University, both in 1982.